Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Velpatasvir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,079Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA approves new formulation Gilead's Epclusa for Kids ages 3 and older with HCV
    FDA approves new formulation Gilead's Epclusa for Kids ages 3 and older with HCV

    10 Jun 2021

    // Jonathan.M SEEKING ALPHA

    https://seekingalpha.com/news/3705521-fda-approves-new-formulation-gileads-epclusa-for-children-ages-3-and-older-with-hcv

    Jonathan.M SEEKING ALPHA
    10 Jun 2021
    Share Share
    FDA OKs Gilead’s paediatric hep C drug
    FDA OKs Gilead’s paediatric hep C drug

    20 Mar 2020

    // Anna Smith PHARMATIMES

    http://www.pharmatimes.com/news/fda_oks_gileads_paediatric_hep_c_drug_1329622

    Anna Smith PHARMATIMES
    20 Mar 2020
    Share Share
    U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir
    U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir

    19 Mar 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200319005700/en

    BUSINESSWIRE
    19 Mar 2020
    Share Share
    Gilead airs first ads for hep C brand Epclusa
    Gilead airs first ads for hep C brand Epclusa

    05 Feb 2019

    // Beth S Bulik FIERCE PHARMA

    https://www.fiercepharma.com/marketing/gilead-airs-first-hep-c-epclusa-campaign-even-as-its-own-generics-way

    Beth S Bulik FIERCE PHARMA
    05 Feb 2019
    Share Share
    Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa®
    Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa®

    08 Jan 2019

    // PRESS RELEASE

    https://www.gilead.com/news-and-press/press-room/press-releases/2019/1/japans-ministry-of-health-labour-and-welfare-approves-gileads-epclusa-sofosbuvirvelpatasvir

    PRESS RELEASE
    08 Jan 2019
    Share Share
    AbbVie's latest hep C push highlights Mavyret's time-to-cure advantage
    AbbVie's latest hep C push highlights Mavyret's time-to-cure advantage

    13 Dec 2018

    // Beth S Bulik FIERCE PHARMA

    https://www.fiercepharma.com/marketing/abbvie-highlights-mavyret-s-8-week-advantage-new-ad-campaign-as-it-continues-its-hep-c

    Beth S Bulik FIERCE PHARMA
    13 Dec 2018
    Share Share